Ronnie Maxwell Lawrence

USPTO Granted Patents = 14 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 62(Granted Patents)

Location History:

Upper Gravenhurst, GB (2021)
Stevenage, GB (2003 - 2023)

Company Filing History:

Smithkline Beecham Corporation

patents

4. 2 out of 176

King's College London

patents

5. 1 out of 9

Nerre Therapeutics Limited

Actimed Therapeutics Limited

patents

Years Active: 2003-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12358862 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use (2025-07-15),

2. 12358861 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use (2025-07-15),

3. 12109192 - Organic acid addition salts of S-pindolol (2024-10-08),

4. 11584741 - Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation (2023-02-21),

5. 11117855 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use (2021-09-14),

6. 11072577 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use (2021-07-27),

7. 10988436 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use (2021-04-27),

8. 10870644 - Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-l,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation (2020-12-22),

9. 8796269 - [object Object] (2014-08-05),

10. 8093242 - Crystalline forms of a pyridine derivative (2012-01-10),

11. 7709677 - Process of preparing arylethanoldiamines (2010-05-04),

12. 7557209 - Process for the preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol (2009-07-07),

13. 7425639 - Process (2008-09-16),

14. 6548523 - Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties (2003-04-15),

Title: The Innovative Journey of Ronnie Maxwell Lawrence

Introduction

Ronnie Maxwell Lawrence, a prominent inventor based in Stevenage, Great Britain, has made significant contributions to the field of therapeutic compounds. With a remarkable portfolio of eight patents to his name, his innovations are paving the way for advancements in medical treatments, particularly in the realm of neurological recovery.

Latest Patents

Among his latest inventions are the crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid, commonly referred to as 'BHBA-001'. This invention focuses on the development of selective retinoic acid receptor beta (RARβ) agonists, specifically targeting RARβ2. The therapeutic applications of this invention are vast, especially in promoting neurite development and regeneration, which is crucial for treating spinal cord injuries and other neurological conditions.

Career Highlights

Throughout his career, Lawrence has worked with notable organizations such as GlaxoSmithKline LLC and SmithKline Beecham Corporation. His experiences in these reputable companies have played a pivotal role in honing his innovative skills and knowledge in pharmacology and therapeutic development.

Collaborations

Collaboration with esteemed colleagues has been a significant part of Lawrence's career. Notably, he has worked alongside Jason William Beames Cooke and Bobby Neal Glover, further enriching his research and innovations through shared expertise and insights.

Conclusion

Ronnie Maxwell Lawrence's innovative spirit and dedication to advancing therapeutic solutions exemplify the impact of inventors in shaping the future of medicine. His latest patent contributions highlight the potential for breakthrough treatments in neurology, further solidifying his role as a pioneering inventor in the field.

This text is generated by artificial intelligence and may not be accurate.